好医生首页 > 新闻中心 > 好医生动态及独家报道

GVK生物和依格斯结成战略合作伙伴

时间:2009年04月27日23:00 来源:好医生网站

GVK Biosciences forms Clinical Research Alliance with Excel PharmaStudies, to conduct trials in India and China

 

GVK BIO – Excel have decided to form an alliance to build on the strengths of each company and offer clients with services that span India and China.  

 

Hyderabad, India (April 14, 2009) – GVK Biosciences (GVK BIO), Asia’s leading integrated research services provider and Excel PharmaStudies (Excel), a leading Chinese Clinical Research Organization announced a strategic alliance to conduct Clinical Trials in Asia.

 

The alliance provides clinical trial sponsors access to the scientific skills, talent pool, flexible resourcing, and cost-effectiveness of both India and China.  India has sponsor friendly regulations and strength in Phase II/III clinical trials; China has strengths in its large market, Phase III and post marketing Phase IV studies; Through the GVK BIO-Excel alliance sponsors will be able to conduct Phase II-IV trials using India and China as required with speed and efficiency.
Under the terms of the arrangement, GVK BIO and Excel will help sponsors conduct and manage Phase II-IV clinical trials, statistical analysis and medical writing.  Any India trial for Excel will be carried out by the GVK BIO clinical research team and will be managed by a core project management team of Excel. Similarly, a GVK BIO China trial will be carried out by the Excel team and managed by GVK BIO’s project management team.

 

“This is a first of a kind alliance between an Indian CRO and a Chinese CRO. The GVK BIO-Excel alliance integrates trial management across India and China and provides sponsors with a single point of contact”, said Manni Kantipudi, President GVK BIO.

 

“It is an important step for Excel, and our clients, to be able to provide full services in both important countries”, said Dr. William Xiong, CEO Excel PharmaStudies.

 

The decision to form such an alliance comes close on heels of GVK Biosciences increased focus on Clinical Development. GVK BIO had recently strengthened its team by hiring Dr. Shoibal Mukherjee, ex-Pfizer as its Clinical Development Head. GVK BIO also added new services in pharmacovigilance and medical writing operating from its Clinical Research Facility in Gurgaon, India.

 

About GVK BIO

 

GVK Biosciences (www.gvkbio.com), Asia’s leading Contract Research Organization, delivers integrated research services to Big Pharma and Biotech companies globally. GVK BIO accelerates the drug discovery and development process of its customers through science and innovation.  GVK BIO has a diverse customer portfolio including 15 Big Pharma companies, Agri & Life-sciences companies, leading biotechs and academic institutions. Headquartered in Hyderabad, India, GVK BIO has more than 1,500 employees spread across research facilities in Hyderabad, Chennai, Mumbai and Gurgaon in India. 

 

About Excel PharmaStudies

 

Excel PharmaStudies, Inc. is a full-service provider of clinical research, registration, biometrics, and training and consultation services. Excel is the leading CRO in China, with more limited operations throughout Asia. With 17 offices worldwide, nearly 300 staff members, and experience working with over 120 of the world's leading global pharmaceutical and biotech companies, Excel PharmaStudies, Inc. has the resources, connections, and expertise needed to help you with all of your drug development needs in Asia.

 

For any further information, please contact: bdcr@gvkbio.com  (or)

 

For GVK Biosciences Private Limited www.gvkbio.com

 

Sharada Alvakonda

 

Dy. General Manager – Corporate Communications

 

GVK Biosciences Private Limited

 

T   +91 40 66929999

 

E   sharada@gvkbio.com

 

参考译文:

 

GVK生物和依格斯结成临床医学研究联盟,以便在印度和中国进行实验。

 

GVK生物和依格斯已经决定结成联盟,以强化各自公司的优势并为覆盖印度和中国两地的客户提供服务。

 

2009年4月14日海德拉巴电,处于亚洲领先地位的一体化研究服务供应商GVK生物(GVK BIO)和一个在中国过处于领先地位的中国临床研究机构依格斯宣布结成战略联盟,以便在亚洲进行临床试验研究。该联盟能够给为临床试验研究提供赞助的赞助商同时获得印度和中国的科研技能、人才储蓄、灵活的资源利用,以及低成本研究。印度有特别有利于赞助商的政策法规,以及第二阶段和第三阶段临床试验方面的优势;中国在其巨大的市场、第三阶段和营销后第四阶段研究方面具有很大优势。借助GVK生物与依格斯所结成的联盟,赞助商将能够在必要的时候使用印度和中国开展第二至第四阶段的研究,而且能获得高速与高效。

 

根据该协议的有关条款,GVK生物和依格斯将帮助赞助商开展和管理第二阶段至第四阶段的临床试验,统计分析和医学写作。任何依格斯在印度的试验将通过GVK生物临床研究小组去执行,将有一个依格斯核心项目管理小组来管理。同样,一个GVK生物在中国进行的试验将由依格斯团队执行,并由GVK生物的项目管理团队去管理。

 

“这是一个印度CRO和一个中国CRO的第一次联盟行为。GVK生物与依格斯之间的联盟整合了印度和中国的实验管理,为赞助商提供了一个单一的联系点。” GVK生物总裁Manni Kantipudi说。

 

“能够在两个重要的国家给我们的客户提供全面的服务,这是对依格斯来说是很重要的一步。”依格斯的CEO  William Xiong博士说。

 

作出成立这样一个联盟决定的来自于GVK生物对于临床开发的日益增长的关注。 GVK生物最近聘用了前辉瑞专家Shoibal穆克杰博士,来担任其临床开发部的负责人。 GVK生物还在其位于印度Gurgaon的临床研究基地中增加了新的服务,药物警戒和医学书面写作。

 

 

关于GVK生物

 

GVK生物(网址:www.gvkbio.com )是一个在亚洲处于领先地位的合同研究组织(CRO)。它在全球范围内为大制药公司和生物技术公司提供一体化的研究服务。 GVK生物通过科学和创新来为客户加速药物发现和开发过程。 GVK生物的客户群体非常多样化,包括15个大型制药公司,农业和生命科学研究公司,一流的生物技术与学术机构。GVK生物的总部设在印度的海得拉巴, 拥有超过1500雇员,其研究设施分布在印度的海得拉巴,晨奈,孟买和古尔冈。

 

关于依格斯

 

依格斯 (北京) 医疗科技有限公司,致力于为客户提供临床研究、注册申报、生物信息统计和培训咨询等全方位专业化服务。作为中国领先的专业合同研究组织(CRO),在整个亚洲也有有限业务。依格斯在全球设有17家办事机构,拥有300余名优秀的员工,已经为120多家大型跨国制药企业和生物技术公司提供过专业服务。凭借丰富的资源优势、广泛的合作伙伴、深厚的专业功底,依格斯将助您在亚洲医药发展一臂之力。(杨勇飞 译)

 

 

欲获取更多相关信息,请联系:bdcr@gvkbio.com

 

 

GVK Biosciences Private Limited的联系方式如下:网址:www.gvkbio.com

 

 

Sharada Alvakonda

 

副总经理 – 负责企业通讯

 

GVK 生物私人有限公司

 

电话:   +91 40 66929999  

 

邮箱:   sharada@gvkbio.com

 

糖皮质激素 | 冠脉疾病诊断 | 丙肝认知调查
惠氏在线医学服务 | 喂养知识大赛 | 精神抑郁
2010年执业医师考试

热点招聘

更多

学术中心特别推荐

学术中心特别推荐

关于我们 | 广告服务 | 欢迎加盟 | 联系我们 | 网站地图 | 郑重声明 | 免费邮箱

 

北京健康在线技术开发有限公司

Copyright © 2000-2013 好医生网站 版权所有 京ICP证040426号

教育部教职成司函[2005]8号 互联网医疗保健信息服务审核同意书 互联网药品信息服务资格证书(京)-经营性-2004-0026

电信与信息服务业务经营许可证书 出版物经营许可证书

免费服务热线:400-810-5790 服务信箱:webmaster@mail.haoyisheng.com  好医生新浪微博  好医生腾讯微博